Revance Therapeutics's Earnings Outlook
Portfolio Pulse from Benzinga Insights
Revance Therapeutics (NASDAQ:RVNC) is set to release its latest quarterly earnings report on November 8, 2023. Analysts estimate an earnings per share (EPS) of $-0.90. The company's past performance shows a trend of missing EPS estimates and subsequent drops in share price. The stock is currently trading at $9.08, down 56.4% over the last 52-week period.
November 07, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Revance Therapeutics is expected to report an EPS of $-0.90 in its upcoming earnings report. The company's history of missing EPS estimates and subsequent share price drops could potentially impact the stock negatively.
Revance Therapeutics has a history of missing EPS estimates, which has consistently led to drops in its share price. Given this trend and the analysts' estimate of a negative EPS for the upcoming quarter, it is likely that the stock price may experience a negative impact in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100